Home › Stargardt Disease › Massachusetts › Boston
Stargardt Disease clinical trials in Boston, MA
5 studies for Stargardt Disease are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of ALK-001 on the Progression of Stargardt Disease
RecruitingPhase 3
- Tufts Medical Center - New England Eye Center, Boston
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
RecruitingObservational study
- Massachusetts Eye and Ear, Boston
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
RecruitingPhase 1/2
- Massachusetts Eye and Ear, Boston
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RecruitingObservational study
- Massachusetts Eye and Ear Infirmary, Boston
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RecruitingPhase 1/2
- Massachusetts Eye and Ear Infirmary, Boston
Stargardt Disease trials in other cities
- Dallas, TX9 studies
- Phoenix, AZ4 studies
- Houston, TX4 studies
- Cincinnati, OH4 studies
- Ann Arbor, MI4 studies
- Gainesville, FL4 studies
- Miami, FL4 studies
- Portland, OR4 studies
- Baltimore, MD3 studies
- Pittsburgh, PA3 studies
- Aurora, CO3 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.